We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Global Blood Therapeutics Inc (GBT) USD0.001

Sell:$32.77 Buy:$32.80 Change: $0.85 (2.66%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:$32.77
Buy:$32.80
Change: $0.85 (2.66%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:$32.77
Buy:$32.80
Change: $0.85 (2.66%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The Company is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.

Contact details

Address:
181 OYSTER POINT BLVD
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (650) 7417700
Website:
https://www.gbt.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GBT
ISIN:
US37890U1088
Market cap:
$2.10 billion
Shares in issue:
65.10 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ted Love
    President, Chief Executive Officer, Director
  • Jeffrey Farrow
    Chief Financial Officer
  • Carrie Krehlik
    Chief Human Resource Officer
  • Kim Smith- Whitley
    Executive Vice President, Head of Research and Development
  • Jung Choi
    Chief Business and Strategy Officer
  • David Johnson
    Chief Commercial Officer
  • Tricia Suvari
    Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.